June 5, 2022 10:20 AM EDTUpdated June 6, 03:44 PM

#ASCO22: Enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

CHICAGO — When Camille Hertzka found out the results of a study showing breast cancer drug Enhertu cut disease progression or death by about half …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: Enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

#AS­CO22: En­her­tu blows chemother­a­py out of the wa­ter, re­defin­ing breast can­cer sub­groups along the way

News Reporter

Senior Reporter

Sign up to read this article for free.

#ASCO22: Enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way